Sponsors (3)
Official title: Amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of cannabis and cannabinoid products, and for other purposes.
Introduced December 15, 2025 by Ronald Lee Wyden · Last progress December 15, 2025
The bill strengthens federal oversight, safety standards, research, and targeted grants to reduce unsafe cannabinoid products, underage use, and cannabis-impaired driving, but does so at measurable federal cost while imposing compliance, administrative, and enforcement risks that may disproportionately affect small businesses, some communities, and drivers.
Consumers (and the public) gain a federal safety and enforcement framework for cannabinoid products—setting product/labeling standards, banned combinations, and enforcement tools—which should reduce adulterated/misbranded products and clarify removal of unsafe items.
Communities with high underage cannabis use, underserved populations, and schools receive increased grant funding, targeted prevention programs, and surveillance of adverse effects—improving prevention, treatment resources, and public-health data to guide interventions.
Drivers and road users benefit from expanded research, standard-setting, and state grants to build lab capacity, enforcement, prevention, and court programs—producing better data on cannabis-impaired driving and targeted education (including young drivers).
Taxpayers will see increased federal spending for research, grants, and programmatic support (tens to low hundreds of millions of dollars per year across FY2026–2030), increasing budgetary costs.
Small businesses and product developers face new compliance costs, broader inspection/seizure and publicity powers, fines, and reputational risks from stricter packaging/labeling/THC rules and broad statutory definitions of regulated compounds.
The bill expands enforcement exposure—age-based sales prohibitions and increased impaired-driving enforcement funding could lead to more stops, tests, prosecutions, and criminal/regulatory interactions for sellers and some drivers (disproportionately affecting some low-income and marginalized groups).
Based on analysis of 6 sections of legislative text.
Creates an FDA regulatory regime for cannabinoid products, expands surveillance and prevention grants for underage use, and funds DOT research/grants to address cannabis-impaired driving.
Creates a new federal regulatory regime for cannabinoid products under the Federal Food, Drug, and Cosmetic Act, defining terms (cannabis, cannabinoid, THC, synthetic cannabinoids), adding new prohibited acts (including sales to under-21s, mixing with alcohol/tobacco/nicotine, certain dosage forms and labeling/serving-size rules), and expanding inspection, seizure, penalty, import/export, and publicity authorities to cover cannabinoid products. Requires USDA, FDA, DOJ, and TTB to jointly recommend a regulatory framework for THC-containing cannabinoid beverages within 60 days. Provides new and expanded public-health funding and grant programs: increases surveillance funding for cannabis-related adverse effects, creates a competitive grant program to prevent underage cannabis use with prioritized funding for underserved communities, and establishes a federally funded program and formula grants administered by DOT/NHTSA to research, prevent, and mitigate cannabis-impaired driving, including data collection, national surveys, model state practices, prevention campaigns, and potential model national impairment standards. The bill authorizes multi-year appropriations for these activities (FY2026–2030).